Clinical trials: Mosquito-Borne Diseases
Malaria in Pregnancy
Daily Co-trimoxazole Prophylaxis to Prevent Malaria in Pregnancy
Malaria is a major contributor of disease burden in Sub-Saharan Africa, and pregnant women and children are the most vulnerable population.
- Trial name
- NCT00711906
- Testing
- Cotrimoxazole, Sulfadoxine-pyrimethamine
- Where
- 2 sites in Zambia
- Volunteers
- 352 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Dengue Fever
A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue)
This is a cluster randomized controlled trial (CRCT) to evaluate the efficacy of Wolbachia-infected A. aegypti mosquito releases in reducing the burden of ARBV infection in Brazil over four years.
- Trial name
- NCT04514107
- Testing
- Brazilian National Dengue Control Program, Wolbachia-infected Aedes aegypti
- Where
- Brazil
- Volunteers
- 5,757 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, PLASMODIUM FALCIPARUM MALARIA
Assessing Vaccine Effectiveness of R21/Matrix-M Across Malaria Transmission Settings (AVERT)
The AVERT study is a prospective observational test-negative case control study evaluating the real-world effectiveness of the R21/Matrix-M malaria vaccine among children younger than 5 years in Burkina Faso and Uganda.
- Trial name
- AVERT (NCT07749911)
- Testing
- R21/Matris-M Malaria vaccine
- Where
- 21 sites in Burkina Faso, Uganda
- Volunteers
- 20,000 people
- Sponsor
- Clinton Health Access Initiative Inc.
Malaria, Falciparum
First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults
This study will assess the safety, tolerability, and pharmacokinetic properties of GSK4425689A monoclonal antibody (mAb) in healthy adults, when administered by either intravenous (IV) or subcutaneous (SC) routes.
- Trial name
- NCT07646353
- Testing
- GSK4425689A SC, GSK4425689A IV
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Anemia
Evaluation of a Comprehensive School Health Programme in Zambia
In Zambia, the health and well-being of children aged 5 to 14 has often been overlooked, leading to various health challenges affecting their development and education.
- Conditions
- Malaria, Anemia, Diarrhea
- Trial name
- NCT06560853
- Testing
- Comprehensive School Health Programme, Deworming and vitamin A supplementation delivery
- Where
- 6 sites in Zambia
- Volunteers
- 28,700 people, healthy volunteers welcome
- Sponsor
- London School of Economics and Political Science
Malaria
Controlled Human Malarial Infection by Intravenous Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults
The study is designed to establish the best dose to safely infect healthy individuals with Plasmodium falciparum sporozoites (PfSPZ) via intravenous (IV) injection.
- Trial name
- NCT01624961
- Testing
- PfSPZ Challenge
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Pregnancy, Malaria
Efficacy of Intermittent Screening and Treatment or Intermittent Preventive Treatment (IPT) With Dihydroartemisinin-Piperaquine, Versus IPT With Sulfadoxine-Pyrimethamine for the Control of Malaria in Pregnancy in Kenya
Malaria in pregnancy (MiP) due to Plasmodium falciparum infection is a major cause of maternal morbidity and poor birth outcomes.
- Trial name
- STOP MiP KENYA (NCT01669941)
- Testing
- IPTp-SP, IPTp-DP, ISTp-DP
- Where
- 4 sites in Kenya
- Volunteers
- 1,546 people
- Sponsor
- Kenya Medical Research Institute
Dengue
Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)
The purpose of this research study is to test a weakened form of an experimental dengue virus challenge at different doses to test if participants develop symptoms or circulating virus in the blood (called viremia).
- Trial name
- NCT05268302
- Testing
- Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose, Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose - Homologous Rechallenge
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Dengue Fever
Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants
The purpose of this study is to assess the humoral immune responses to three different dose schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) administered subcutaneously in healthy participants between 2 and <18…
- Trial name
- NCT02302066
- Testing
- Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
- Where
- 3 sites in Dominican Republic, Panama and 1 more
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Takeda
Filarial; Infestation
Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection
Diethylcarbamazine (DEC) essentially a micro-filaricidal drug is given for 12 days as standard treatment for the clearance of W. bancrofti infection.
- Trial name
- NCT02005653
- Testing
- Diethylcarbamazine, Albendazole, Doxycycline
- Where
- India
- Volunteers
- 146 people
- Sponsor
- Indian Council of Medical Research
Plasmodium Falciparum Malaria
Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria
The primary trial objective is to determine the clinically effective dose of orally administered pyronaridine/artesunate (Pyramax®, PA) with a 3:1 ratio to treat adults with acute, symptomatic, uncomplicated P.
- Trial name
- NCT01594931
- Testing
- pyronaridine/artesunate
- Where
- 6 sites in Cambodia, Indonesia and 4 more
- Volunteers
- 477 people
- Sponsor
- Medicines for Malaria Venture
Dengue
Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain
To evaluate the effectiveness of candidate dengue vaccine formulations, it is prudent to develop an appropriate challenge model.
- Trial name
- NCT02372175
- Testing
- Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria, Malnutrition, Child
Assessment of a Combined Strategy of SMC + Nutrients Supplementation to Tackle Malaria and Malnutrition
Malaria and malnutrition represent major public health concerns worldwide especially in Sub-Sahara Africa. Despite implementation of Seasonal Malaria Chemoprophylaxis (SMC), an intervention aimed at reducing malaria prevalence…
- Trial name
- SMC-NUT (NCT04238845)
- Testing
- AQSP Administration, Supplementation with Plumpy'Doz, Supplementation with Vitamin A
- Where
- Burkina Faso
- Volunteers
- 1,059 people, healthy volunteers welcome
- Sponsor
- Institut de Recherche en Sciences de la Sante, Burkina Faso
Malaria
Prenatal Iron and Malaria Study
The purpose of this study is to compare the presence of Plasmodium infection in parturient women who antenatally received a combination of iron-fortified foods with iron supplements versus iron-fortified foods only.
- Trial name
- PIMAL (NCT01308112)
- Testing
- iron
- Where
- Kenya
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso
Resistance to antimalarial drugs represents a major obstacle for controlling malaria in endemic countries, so that most sub-Saharan countries have changed their antimalarial drug policy to the new Artemisinin Containing…
- Trial name
- NCT00808951
- Testing
- Artesunate-amodiaquine, Artemether-lumefantrine
- Where
- Burkina Faso
- Volunteers
- 440 people
- Sponsor
- Centre Muraz
Japanese Encephalitis, Japanese Encephalitis Vaccine
A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2
Japanese encephalitis (JE) live attenuated vaccine SA14-14-2 has been in use for more more than 20 years in Asia. JE vaccine SA14-14-2 is licensed in India and has been widely used since 2006.
- Trial name
- NCT01656200
- Testing
- Live attenuated Japanese encephalitis vaccine SA14-14-2
- Where
- 2 sites in India
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Indian Institute of Science
Malaria
A Challenge Study to Assess the Safety, Immunogenicity and Efficacy of a Malaria Vaccine Candidate
This is an open-label, multi-centre Phase I/IIa dose escalation blood-stage malaria CHMI trial to assess the safety, immunogenicity and efficacy of the candidate malaria vaccine RH5.1/AS01.
- Trial name
- NCT02927145
- Testing
- RH5.1/ ASO1
- Where
- 2 sites in United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Vivax Malaria
Tafenoquine and ACTs (TADORE- Plus)
A trial designed to determine whether there is a clinically significant drug-drug interaction of tafenoquine with DHA-piperaquine or artesunate-pyronaridine using a control arm with radical cure given at the end of follow up…
- Trial name
- TADORE+ (NCT07060794)
- Testing
- Tafenoquine plus DHA-Piperaquine, Tafenoquine plus Artesunate-pyronaridine
- Volunteers
- 507 people
- Sponsor
- Menzies School of Health Research
Yellow Fever Vaccine, Yellow Fever
Yellow Fever Vaccine on Statin/ Non Statin Subjects
Since the 1st pandemic of the 21st century caused by SARS coronavirus, the world has experienced outbreaks of swine origin H1N1 influenza, Ebola and Zika viruses, which have all resulted in global health crises.
- Trial name
- NCT03116802
- Testing
- Stamaril (live attenuated yellow fever vaccine)
- Where
- Singapore
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Singapore General Hospital
Dengue, Dengue Hemorrhagic Fever
Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America
Primary objectives: To describe the immune response to each dengue serotype before and after each vaccination with sanofi pasteur's CYD dengue vaccine.
- Conditions
- Dengue, Dengue Hemorrhagic Fever, Dengue Virus, Dengue Fever
- Trial name
- NCT00993447
- Testing
- CYD Dengue Vaccine, Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis
- Where
- 4 sites in Colombia, Honduras and 2 more
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.